1. The pharmaceutical components include (2R, 3R) - 2 - {3 - [amine (methyl) benzene} - 3 - [(4 - (1-oxidopiridin-4-il) benzodiazepine], methyl butyrate or a medically acceptable formate and an active acid compound acceptable on the drug, Either the water of the composition dissolves or disperses, or the preparation procedure of the composition, A the method of treating patients with these compounds can be improved by the use of Xa. Requirements 2 inhibitors；The compounds were selected from citric acid, acetic acid, glyceric acid, lactic acid, pyridinic acid, Medina acid, suc cynic acid, gluconic acid, niacin, phenylpropionic acid, tantalic acid, anthrax acid, potato acid, potato acid, hydrochloric acid, hydroxy acid, etc. Benzoic acid, hydroxybenzoic acid, phenylacetic acid, kinetic acid, hydrochloric acid, benzoic acid, 2-phenylbenzoic acid, acrylonitrile acid, methane, 2-hydroxysulfonamide acid, ammonia acid,Acetylhydrochloric acid or amino acid or mineral acid, consisting of hydrochloric acid or phosphoric acid or salts, amino acids and mineral acids of these organic acids, or a mixture of one or more acid compounds. Claim 14: pharmaceutical ingredients in claims 1 to 13 for the treatment of acute myocardial infarction, primary myocardial infarction in St. Louis, unstable angina, tromboelia, acute vascular abrasions related to salpingotherapy, coronary artery transitional subcutaneous angioplasty, Transient ischemia, cerebral infarctionOn and offUna composición farmacéutica que comprende (2R,3R)-2-{3-[amino(imino)metil]bencil}-3-{[4-(1-oxidopiridin-4-il)benzoil]amino}butanoato de metilo o una sal farmacéuticamente aceptable del mismo y un compuesto reactivo ácido farmacéuticamente aceptable, o a una solución o dispersión acuosa de la composición así como a un procedimiento para la preparación de la misma, a métodos para usar tales composiciones para tratar a sujetos que sufren enfermedades que se pueden mejorar por la administración de un inhibidor del Factor Xa
